Upregulation of the ATR-CHEK1 pathway in oral squamous cell carcinomas

Genes Chromosomes and Cancer

Volumn 53, Issue 1, 2014, Pages 25-37

  Parikh, Rahul A ^a,b   Appleman, Leonard J ^a,b   Bauman, Julie E ^a,b   Sankunny, Madhav ^c   Lewis, Dale W ^c   Vlad, Anda ^b,d   Gollin, Susanne M ^b,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATR PROTEIN; CHECKPOINT KINASE 1; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; ATR GENE; CARCINOMA CELL; CELL CYCLE G0 PHASE; CELL POPULATION; CELL SURVIVAL; CHEK1 GENE; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA DAMAGE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOSS; GENE STRUCTURE; GENE TRANSLOCATION; GENETIC GAIN; HUMAN; HUMAN CELL; HUMAN TISSUE; IONIZING RADIATION; MOUTH SQUAMOUS CELL CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIOSENSITIVITY; UPREGULATION;

ATAXIA TELANGIECTASIA;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 3; DNA DAMAGE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE DOSAGE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MOUTH NEOPLASMS; PROTEIN KINASES; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC; UP-REGULATION;

EID: 84887623620     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22115     Document Type: Article

References (45)

1. Argiris A, Karamouzis MV, Raben D, Ferris RL. 2008. Head and neck cancer. Lancet 371:1695-1709.
2. Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S. 2005. Hypoxia-induced dedifferentiation of tumor cells-a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 16:554-563.
3. Bakkenist CJ, Kastan MB. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421:499-506.
4. Bartek J, Lukas J. 2011. DNA repair: Cyclin D1 multitasks. Nature 474:171-172.
5. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. 2010. The landscape of somatic copy-number alteration across human cancers. Nature 463:899-905.
6. Bockmuhl U, Schluns K, Kuchler I, Petersen S, Petersen I. 2000. Genetic imbalances with impact on survival in head and neck cancer patients. Am J Pathol 157:369-375.
7. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. 2000. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 60:2108-2112.
8. Casper AM, Nghiem P, Arlt MF, Glover TW. 2002. ATR regulates fragile site stability. Cell 111:779-789.
9. Chung CH, Gillison ML. 2009. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 15:6758-6762.
10. Coquelle A, Toledo F, Stern S, Bieth A, Debatisse M. 1998. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell 2:259-265.
11. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML. 2008. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261-269.
12. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917.
13. Gollin SM. 2001. Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck 23:238-253.
14. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91.
15. Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ. 2002. Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 22:1834-1843.
16. Hammond EM, Dorie MJ, Giaccia AJ. 2003. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem 278:12207-12213.
17. Hammond EM, Dorie MJ, Giaccia AJ. 2004. Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation. Cancer Res 64:6556-6562.
18. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
19. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-674.
20. Helt CE, Cliby WA, Keng PC, Bambara RA, O'Reilly MA. 2005. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J Biol Chem 280:1186-1192.
21. Huang X, Gollin SM, Raja S, Godfrey TE. 2002. High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci USA 99:11369-11374.
22. Iacobucci I, Cattina F, Pomella S, ILonetti A, Derenzini E, Brighenti E, Ferrari A, Papayannidis C, Falzacappa MVV, Guadagnuolo V, Aluigi M, Ottaviani E, Formica S, Abbenante MC, Soverini S, Russo D, Pane F, Pellicci PG, Baccarani M, Martinelli G. 2011. The novel small molecule Chk1/Chk2 inhibitor PF-00477736 (Pfizer) is highly active as single agent in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). In: 53rd ASH Annual Meeting and Exposition. Blood (ASH Annual Meeting Abstracts), Nov 2011;118:76.
23. Jin Y, Jin C, Wennerberg J, Hoglund M, Mertens F. 2002. Cyclin D1 amplification in chromosomal band 11q13 is associated with overrepresentation of 3q21-q29 in head and neck carcinomas. Int J Cancer 98:475-479.
24. Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, Zagozdzon A, Goswami T, Wang YE, Clark AB, Kunkel TA, van Harn T, Xia B, Correll M, Quackenbush J, Livingston DM, Gygi SP, Sicinski P. 2011. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 474:230-234.
25. Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Isaacs R, Kaufmann SH. 2012. Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias. Clin Cancer Res 18:6723-6731.
26. Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H. 2012. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest 122:1541-1552.
27. Martin CL, Reshmi SC, Ried T, Gottberg W, Wilson JW, Reddy JK, Khanna P, Johnson JT, Myers EN, Gollin SM. 2008. Chromosomal imbalances in oral squamous cell carcinoma: examination of 31 cell lines and review of the literature. Oral Oncol 44:369-382.
28. McNeely SC, Burke TF, DurlandBusbice S, Barnard DS, Marshall MS, Bence AK, Beckmann RP. 2011. LY2606368, a second generation Chk1 inhibitor, inhbiits growth of ovarian carcinoma xenografts either as monotherapy or in combination with standard-of-care agents. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. San Francisco, CA: AACR.
29. Meyn MS. 1999. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin Genet 55:289-304.
30. Parikh RA, White JS, Huang X, Schoppy DW, Baysal BE, Baskaran R, Bakkenist CJ, Saunders WS, Hsu LC, Romkes M, Gollin SM. 2007. Loss of distal 11q is associated with DNA repair deficiency and reduced sensitivity to ionizing radiation in head and neck squamous cell carcinoma. Genes Chromosomes Cancer 46:761-775.
31. Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A, Cliby WA, Sarkaria J, Beale G, Edmondson RJ, Curtin NJ. 2011. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer 105:372-381.
32. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM. 2007. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357:2552-2561.
33. Prevo R, Fokas E, Reaper PM, Charlton PA, Pollard JR, McKenna WG, Muschel RJ, Brunner TB. 2012. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther 13:1072-1081.
34. Reshmi SC, Huang X, Schoppy DW, Black RC, Saunders WS, Smith DI, Gollin SM. 2007. Relationship between FRA11F and 11q13 gene amplification in oral cancer. Genes Chromosomes Cancer 46:143-154.
35. Schenk EL, Koh BD, Flatten KS, Peterson KL, Parry D, Hess AD, Smith BD, Karp JE, Karnitz LM, Kaufmann SH. 2012. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Clin Cancer Res 18:5364-5373.
36. Shiloh Y. 2001. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 11:71-77.
37. Shiloh Y. 2003. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3:155-168.
38. Siegel R, Naishadham D, Jemal A. 2013. Cancer statistics, 2013. CA Cancer J Clin 63:11-30.
39. Sinha P, Hackman T, Nussenbaum B, Wu N, Lewis JS, Jr., Haughey BH. Transoral laser microsurgery for oral squamous cell carcinoma: oncologic outcomes and prognostic factors. Head Neck. 2013 Jun 1. doi: 10.1002/hed.23293. [Epub ahead of print].
40. Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, Helleday T. 2005. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 7:195-201.
41. Uhrhammer N, Fritz E, Boyden L, Meyn MS. 1999. Human fibroblasts transfected with an ATM antisense vector respond abnormally to ionizing radiation. Int J Mol Med 4:43-47.
42. Vance S, Liu E, Zhao L, Parsels JD, Parsels LA, Brown JL, Maybaum J, Lawrence TS, Morgan MA. 2011. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle 10:4321-4329.
43. Wang X, Khadpe J, Hu B, Iliakis G, Wang Y. 2003. An overactivated ATR/CHK1 pathway is responsible for the prolonged G2 accumulation in irradiated AT cells. J Biol Chem 278:30869-30874.
44. White JS, Weissfeld JL, Ragin CC, Rossie KM, Martin CL, Shuster M, Ishwad CS, Law JC, Myers EN, Johnson JT, Gollin SM. 2007. The influence of clinical and demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines. Oral Oncol 43:701-712.
45. Wu W, Bi C, Bence AK, Um SL, Yan B, Starling JJ, Marshall MS, Beckmann RP. 2011. Antitumor activity of Chk1 inhibitor LY2606368 as a single agent in SW1990 human pancreas orthotopic tumor model. Cancer Res 72:Abstract nr 1776.